Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial
about
sameAs
Current and future treatment options in SIADHReview of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies"Nihilism" of chronic heart failure therapy in children and why effective therapy is withheldManagement of Patients Admitted with Acute Decompensated Heart FailureReview of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug InteractionsHyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy.Current issues for nurse practitioners: Hyponatremia.Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study.Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South IndiaIncreased renal ENaC subunits and sodium retention in rats with chronic heart failure.Tolvaptan: the evidence for its therapeutic value in acute heart failure syndromeANG II receptor subtype 1a gene knockdown in the subfornical organ prevents increased drinking behavior in bile duct-ligated ratsDiuretic use in heart failure and outcomes.Clinical practice guideline on diagnosis and treatment of hyponatraemia.The cardiorenal syndrome: a reviewAortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.Tolvaptan, hyponatremia, and heart failure.Novel pharmacological treatments for heart failure.A review of drug-induced hypernatraemia.Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials.Loop diuretics in acute heart failure: beyond the decongestive relief for the kidneyConsequences of inadequate management of hyponatremia.Vasopressin receptor antagonists in the management of acute heart failure.Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin.Hyponatraemia for the clinical endocrinologist.Chronic heart failure: an overview of conventional treatment versus novel approaches.Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.Hyponatremia and heart failure--treatment considerations.Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure.Medical and ventilatory treatment of acute heart failure: new insights.Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials.Vasopressin antagonists: role in the management of hyponatremia.Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.Intracerebroventricular losartan infusion modulates angiotensin II type 1 receptor expression in the subfornical organ and drinking behaviour in bile-duct-ligated rats.Vasopressin antagonists in the management of heart failure.Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.Conivaptan: a step forward in the treatment of hyponatremia?Vasopressin-receptor antagonist therapy in patients with hyponatraemia.
P2860
Q24652519-5F737A1C-8E33-4605-A84B-2C62510AEAFEQ26746907-C217D57B-0FB9-4527-9226-37F254624205Q26768688-3BE36A9B-E88A-4739-86FD-6F4AF25EBD43Q26786085-187888A4-8E27-491E-A1F9-9D472E01E904Q26995169-9E3DD01E-1E1F-4A1E-8F72-9536009E10C1Q30432267-6C93DDC9-201E-4088-AD44-52CC02BF868CQ33304369-BC6AFDC1-7F57-462B-893F-9C00B3D986F1Q33712822-053C574E-54F6-44C1-97E2-D50AC6539B7EQ33775812-36C9BDC8-E0B9-4A3C-B7D8-932FCEBD0DB9Q33796947-E352624B-3603-45BA-B2C7-78FB527842CDQ33973976-974BB8D3-DA39-46EA-9A07-5DC4FEDEEA35Q34201130-41505991-2732-46DB-8E70-8CA38774FB08Q34357452-A04174CC-640B-4495-98AD-79A117218D33Q34406779-5B297EA0-3B21-432D-8A3E-2701C89F26B6Q34495307-4E0089C0-644E-48E3-A1BA-C37700794FBCQ34512883-76FAE282-FF89-4DDE-B81B-902EBF3DD7FBQ35026759-63487A08-55ED-43E6-A4C4-C2236EE6284DQ35570949-D2A4623A-1CD7-44D8-B71F-89D298974D53Q35574010-40653E7D-F573-4D23-B04B-5AEFA3024334Q35753495-D7BB981B-C710-4AC8-91CE-D0B12AB92742Q35763002-78FE4BA8-8237-4FCE-8150-A36D81176653Q36024026-F9793E01-11B9-49F5-A9E6-963DF3BFFD6DQ36138277-AAADC0BA-FDC3-4A09-9A48-9D815430F5A2Q36145836-0A7BC133-601C-47A9-8BF6-2369DC2A8770Q36229143-944EF18C-DB0A-4E5B-B22A-27AC473A4E54Q36266368-9A702284-1295-4E79-8310-FF05031FA9F1Q36321764-797BDFCD-BEC7-4D1A-BAEE-008C39127C2AQ36351998-3F350C6D-F02C-4129-80CF-C7A5BCC5BD85Q36376174-9C0622D5-0DBA-41F7-911D-6AD3F00FC112Q36392706-248FC8FC-DB1F-4821-B6B6-A455E78F22AAQ36429719-70BA5B8C-CBFA-48DD-A3A9-8B8F419DB843Q36438459-28F449E6-ED1C-40F5-A25D-9321B6C91744Q36511449-B9988F1C-E250-44C7-89E4-B3B752F5BFC0Q36534664-01282EF2-F4A3-4EE7-BB2D-1CB272E2E6A6Q36684711-B954A145-8A93-432C-9C02-B5A826286852Q36711459-917FD28D-24B2-45DB-A8BF-615146AD992DQ36752115-A4E508FE-3BE5-4B47-9117-F8BECA4016BFQ36776537-F5EFFB67-D460-4640-83BA-0E6FEC377286Q36823541-9CB4C9C1-261D-458E-B0EF-CE6C4F8E17CEQ36896500-9F5BC5A5-FFF2-4AC3-BA7F-6767A38CDBC0
P2860
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@ast
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@en
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@nl
type
label
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@ast
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@en
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@nl
prefLabel
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@ast
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@en
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@nl
P2093
P921
P3181
P1433
P1476
Vasopressin V2-receptor blocka ...... double-blind, randomized trial
@en
P2093
Cesare Orlandi
Frank Czerwiec
Imran Niazi
John Ouyang
Jun-ichi Kambayashi
Manuela Zampino
P304
P3181
P356
10.1161/01.CIR.0000070422.41439.04
P407
P577
2003-06-03T00:00:00Z